Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. - Wikidata - awgldk - TriplyDB

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.

http://www.wikidata.org/entity/Q34789146

about

B7-H5 costimulates human T cells via CD28H Immunotherapy in the treatment of non-small cell lung cancer 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137 Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies.A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells.Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.Interleukin-6 induces Gr-1+CD11b+ myeloid cells to suppress CD8+ T cell-mediated liver injury in mice Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines Targeting CD137 enhances the efficacy of cetuximab.Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.Role of 4-1BB receptor in the control played by CD8(+) T cells on IFN-gamma production by Mycobacterium tuberculosis antigen-specific CD4(+) T Cells ProtEx technology for the generation of novel therapeutic cancer vaccines Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy Dendritic-cell-based therapeutic cancer vaccines Targeting CD8+ T-cell tolerance for cancer immunotherapy.Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis.CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway.Replicase-based plasmid DNA shows anti-tumor activity.Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease.Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease.CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype Using antibodies in tumour immunotherapy.B7-H1-targeted immunotherapy for head and neck cancer.Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent.Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer.

P2860

Q24295841-67C7C13D-B787-491C-A025-53E7972A51A0 Q27000382-C041EDA7-E2D6-4EBB-9F99-30D5289DD2FE Q27012963-AD9D9E44-FF71-47A5-BEC0-DC45B670A511 Q27027633-F27F92E5-CAD9-4958-8CEB-E73FC037543A Q28537820-37740223-EB83-4785-A122-8DADED584D78 Q28592282-5F0E33C5-F940-46CF-AE27-22D33336AA8C Q30430481-975B4533-5A67-46BF-9211-4DE244EA3979 Q30873726-ECB265A2-2D12-4A31-A890-797B726A5F72 Q33426409-ED4C2CCC-6A75-40A9-A8E3-0CB38100B356 Q33586493-1D3906CA-E32E-4426-9D2F-FEB62D36F879 Q33722711-6175D59F-EE92-4AD5-A130-2B9A3CCEBB11 Q33730129-5F7FC01B-A25C-43F1-A845-5836301E25A8 Q33843364-195BD33C-BEB9-4E10-AD91-FE63B2AE7C44 Q33855420-2BD661D0-D254-4975-AAE4-54E1C31F2702 Q33857971-15C6A4D5-327A-4AED-9F0F-D32CD9E37B20 Q33872482-F2E155A8-598B-4CE6-AC4F-BCA7B84626C2 Q33887448-972581F8-A3B3-4921-9E9C-FB384F7853C6 Q33900380-397FD2AF-4696-46B2-9C01-12792C231837 Q34048819-90F08E23-F859-4F08-AA93-DECE339CDA73 Q34052580-EE2BCC3C-8CDD-4E26-91C0-2E1D85BC4B3B Q34065110-BF63035C-43D2-4E15-839E-A92351638A2D Q34122678-E6E1EC8B-5F67-4F5B-A958-102B3A616F0E Q34137777-DDB8B57E-F97C-4463-93E4-BFC25F89AA94 Q34180031-337E7972-6179-4FD4-B7F3-E034D7D350ED Q34360094-877F7EE5-1574-49EF-98F1-5AAB133345DF Q34432692-75B9A312-CB86-4724-9D99-C2E7D56C852F Q34468358-49CF7273-D632-4896-B862-949A817330EB Q34707604-4CBB4D58-1BDC-4B20-B84D-06A857E73ACE Q34707621-0C082BB7-1AFA-4EBB-81C0-4FDF6E9E48B9 Q34778611-FD3000F7-559B-447E-92E4-4F33483B0BE6 Q35051306-F50CE1F9-212E-4A9C-91FA-4E15D932F308 Q35144042-DEA788B6-605A-427F-999B-32A1B0AAAFE0 Q35780315-66901801-AD2A-43D5-BB22-A6ECDB8A2761 Q35804422-B1AA660F-E6B0-4302-83F0-5B5F2201B104 Q35828831-C5E9398B-5B23-499A-B03A-798829657C5B Q35842612-EAAE2DE1-D8B0-4F9C-8EAF-4CEAE8C4EBD1 Q35907010-59BA8585-6F52-4409-84D8-636A43D79E9E Q35987596-2B0A7E27-A237-424E-AA86-D81928852155 Q36057487-9D45F822-25A7-4E04-A4B4-9B4594785E9E Q36174218-AD2DD809-EC68-41F7-8FF4-08B3ED0A4792

P2860

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.

http://www.wikidata.org/entity/Q34789146

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Provision of antigen and CD137 ...... of poorly immunogenic tumors.

@ast

Provision of antigen and CD137 ...... of poorly immunogenic tumors.

@en

Provision of antigen and CD137 ...... of poorly immunogenic tumors.

@nl

type

label

Provision of antigen and CD137 ...... of poorly immunogenic tumors.

@ast

Provision of antigen and CD137 ...... of poorly immunogenic tumors.

@en

Provision of antigen and CD137 ...... of poorly immunogenic tumors.

@nl

prefLabel

Provision of antigen and CD137 ...... of poorly immunogenic tumors.

@ast

Provision of antigen and CD137 ...... of poorly immunogenic tumors.

@en

Provision of antigen and CD137 ...... of poorly immunogenic tumors.

@nl

P1433

Q34789146-31D24A26-C44F-4A41-80D1-FCC34D9DFF57

P1476

Q34789146-4FBEC850-B3AC-48B0-AFB3-EB73D9233915

P2093

Q34789146-01E51CE3-744A-4506-8CE7-9674E25F3C74

Q34789146-1C327EE9-F1C4-4598-801D-D664CFCE4010

Q34789146-3CC059B2-FB00-438D-8AB5-DF092A17342E

Q34789146-74690EBE-1026-455B-BD84-BD02D967C66D

Q34789146-BC57D58D-28BB-47BA-84D9-321F74ED0761

Q34789146-CCD10001-1959-4698-AC46-281428113BBD

Q34789146-DB6A55B8-B72C-47CC-BC58-DD82CA4D1678

Q34789146-E4F21025-621F-4B6C-91B4-F77808EF0766

Q34789146-F9492D99-A2A9-4B37-A030-EBEB2BC3AD33

P2860

Q34789146-0679CAE7-1185-47AF-98F6-FFC395B054D3

Q34789146-06B88487-745A-4CC9-9D47-4D29F85A83BB

Q34789146-128147FF-2571-4E36-AFA3-10624797FFF5

Q34789146-2105E298-38D4-45D4-8652-DE1D65A98312

Q34789146-259C408B-B79A-4A6A-8E27-A4FD9B5E0725

Q34789146-34B70BD2-8AC3-43F8-9645-50798FDE1C3E

Q34789146-37A28530-87D3-4C96-A211-F71EAA229EA6

Q34789146-431C2268-B347-4290-B535-DD761DB48BB3

Q34789146-4FBF674A-01D2-4C8D-963E-F334BB0875B4

Q34789146-5435EE4D-170B-4C32-9146-06BBCA609CA8

P304

Q34789146-700F5A94-7C60-495F-B945-9663526201A7

P31

Q34789146-CFF6131A-F4F6-4F11-A258-EF3A6FF75A75

P356

Q34789146-7CB9AD63-C52C-4796-B7AF-9AFD5E03E19B

P407

Q34789146-40447CEF-21E1-40AA-AAD2-C6E898E2BFE8

P433

Q34789146-5682FFFA-CC4B-4675-BE78-62AC19C28340

P478

Q34789146-70AF0D07-2A04-4F7A-898E-B40289D0D244

P577

Q34789146-E9D79C48-94AE-47F0-80A7-0FA74FD73B30

P698

Q34789146-D64B2DE1-5BBD-4EE8-B124-34528E6070BA

P921

Q34789146-5E7E7D98-1455-4179-BC4A-7CC09A02420C

P932

Q34789146-89FC79C1-9AB5-44B5-846C-AEFD69E07271

P356

P1433

Journal of Clinical Investigation

P1476

Provision of antigen and CD137 ...... of poorly immunogenic tumors.

@en

P2093

Aaron J Johnson

http://www.w3.org/2001/XMLSchema#string

Andrei I Chapoval

http://www.w3.org/2001/XMLSchema#string

Dallas B Flies

http://www.w3.org/2001/XMLSchema#string

Gefeng Zhu

http://www.w3.org/2001/XMLSchema#string

Koji Tamada

http://www.w3.org/2001/XMLSchema#string

Larry R Pease

http://www.w3.org/2001/XMLSchema#string

Lieping Chen

http://www.w3.org/2001/XMLSchema#string

Ryan A Wilcox

http://www.w3.org/2001/XMLSchema#string

Scott E Strome

http://www.w3.org/2001/XMLSchema#string

P2860

CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand

Prevalent class I-restricted T-cell response to the Theiler's virus epitope Db:VP2121-130 in the absence of endogenous CD4 help, tumor necrosis factor alpha, gamma interferon, perforin, or costimulation through CD28.

Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes.

Modulation of the immune response through 4-1BB.

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16.

B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.

Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses

P304

651-659

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI0214184

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11877473

http://www.w3.org/2001/XMLSchema#string

P921

P932

150893

http://www.w3.org/2001/XMLSchema#string